BR112013020874A2 - composto, regime, método para a preparação do referido composto, e, uso de um composto - Google Patents
composto, regime, método para a preparação do referido composto, e, uso de um compostoInfo
- Publication number
- BR112013020874A2 BR112013020874A2 BR112013020874-0A BR112013020874A BR112013020874A2 BR 112013020874 A2 BR112013020874 A2 BR 112013020874A2 BR 112013020874 A BR112013020874 A BR 112013020874A BR 112013020874 A2 BR112013020874 A2 BR 112013020874A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- preparing
- compounds
- regimen
- receptor activator
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
composto, regime, método para a preparação do referido composto, e, uso de um composto o presente pedido fornece novos compostos de aminoindano e métodos para preparar e usar estes compostos. estes compostos são úteis no tratamento de dor e/ou coceira em pacientes por administração de um ou mais dos compostos a um paciente. os métodos incluem a administração de um composto de fórmula (i) ou (11) e um ativador de receptor de trpv 1. em uma modalidade, o ativador do receptor de trpv1 é lidocaína.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161444379P | 2011-02-18 | 2011-02-18 | |
US61/444379 | 2011-02-18 | ||
PCT/US2012/025759 WO2012112969A1 (en) | 2011-02-18 | 2012-02-18 | Aminoindane compounds and use thereof in treating pain |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013020874A2 true BR112013020874A2 (pt) | 2019-05-21 |
Family
ID=45787355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013020874-0A BR112013020874A2 (pt) | 2011-02-18 | 2012-02-18 | composto, regime, método para a preparação do referido composto, e, uso de um composto |
Country Status (16)
Country | Link |
---|---|
US (1) | US8865741B2 (pt) |
EP (3) | EP3363437B8 (pt) |
JP (1) | JP6184328B2 (pt) |
KR (4) | KR20200125765A (pt) |
CN (2) | CN103547566B (pt) |
AU (5) | AU2012219254B2 (pt) |
BR (1) | BR112013020874A2 (pt) |
CA (1) | CA2826648C (pt) |
DK (2) | DK3363437T3 (pt) |
ES (2) | ES2675510T3 (pt) |
HK (1) | HK1248704A1 (pt) |
IL (1) | IL227967A (pt) |
MX (1) | MX348961B (pt) |
RU (2) | RU2016151688A (pt) |
UA (1) | UA112769C2 (pt) |
WO (1) | WO2012112969A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8809372B2 (en) | 2011-09-30 | 2014-08-19 | Asana Biosciences, Llc | Pyridine derivatives |
EP2771320B1 (en) | 2011-10-24 | 2016-06-22 | Endo Pharmaceuticals Inc. | Cyclohexylamines |
WO2014028675A1 (en) * | 2012-08-15 | 2014-02-20 | Endo Pharmaceuticals Inc. | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis |
WO2014124222A1 (en) | 2013-02-08 | 2014-08-14 | General Mills, Inc. | Reduced sodium food products |
TWI799366B (zh) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | 胱胺酸結骨架平臺 |
CN106214678B (zh) * | 2016-07-26 | 2020-12-29 | 上海璃道医药科技有限公司 | 苯酮类药物的用途 |
KR20210099051A (ko) * | 2018-11-30 | 2021-08-11 | 아사나 바이오사이언시스 엘엘씨 | 활성 약학 성분의 개선된 안정성을 위한 제형물, 방법, 키트, 및 투여형 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE760018A (fr) | 1969-12-19 | 1971-06-08 | Christiaens Sa A | Nouveau derives du 2-amino-indane, leur preparation et leur utilisation |
ZA738419B (en) * | 1972-11-06 | 1974-09-25 | Christiaens Sa A | New derivatives of 2-aminoindane,the preparation and use thereof |
US5411738A (en) | 1989-03-17 | 1995-05-02 | Hind Health Care, Inc. | Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine |
US5190956A (en) | 1990-09-07 | 1993-03-02 | Schering Corporation | Certain N-substituted 3-oximino-2,4-dioxoquinolin-2,4-(1H)diones useful for treating viral infections |
US5344836A (en) | 1991-11-11 | 1994-09-06 | Ono Pharmaceutical Co., Ltd. | Fused benzeneoxyacetic acid derivatives |
EP0804434A1 (en) | 1994-08-02 | 1997-11-05 | MERCK SHARP & DOHME LTD. | Azetidine, pyrrolidine and piperidine derivatives |
JP3471122B2 (ja) | 1995-04-26 | 2003-11-25 | アルケア株式会社 | 医療用粘着配合物 |
GB9523243D0 (en) | 1995-11-14 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
SE508357C2 (sv) | 1996-01-02 | 1998-09-28 | Kay Laserow | Mätinstrument för mätning av smärta jämte ett förfarande för att med ett mätinstrument mäta smärta |
GB9610979D0 (en) | 1996-05-24 | 1996-07-31 | Merck Sharp & Dohme | Therapeutic agents |
WO1998024428A1 (en) * | 1996-12-02 | 1998-06-11 | Brigham & Women's Hospital, Inc. | Long-acting local anesthetics |
SE9604751D0 (sv) | 1996-12-20 | 1996-12-20 | Astra Ab | New therapy |
US6623040B1 (en) | 1997-09-03 | 2003-09-23 | Recot, Inc. | Method for determining forced choice consumer preferences by hedonic testing |
CN1814589A (zh) * | 1999-06-10 | 2006-08-09 | 布里奇药品有限公司 | 皮肤麻醉剂 |
CA2376819C (en) * | 1999-06-10 | 2008-09-02 | Bridge Pharma, Inc. | 2-aminoindane derivatives as dermal anesthetic agents |
US6858577B1 (en) | 1999-06-29 | 2005-02-22 | Ortho-Mcneil Pharmaceutical, Inc. | Indole peptidomimetics as thrombin receptor antagonists |
US6630451B1 (en) | 1999-06-29 | 2003-10-07 | Orthomcneil Pharmaceutical, Inc. | Benzimidazolone peptidometics as thrombin receptor antagonist |
AU5895500A (en) | 1999-06-29 | 2001-01-31 | Cor Therapeutics, Inc. | Novel indazole peptidomimetics as thrombin receptor antagonists |
AU6824700A (en) | 1999-07-20 | 2001-02-05 | Novartis Ag | Organic compounds |
WO2001036381A1 (fr) | 1999-11-15 | 2001-05-25 | Nissan Chemical Industries, Ltd. | Composes hydrazone et pesticides |
CZ20031028A3 (cs) | 2000-10-12 | 2003-08-13 | Merck & Co., Inc. | Aza- a polyazanaftalenylkarboxamidy |
DE60138411D1 (de) | 2000-10-13 | 2009-05-28 | Alza Corp | Vorrichtung und verfahren zum durchstechen der haut mit micronadeln |
MXPA03003815A (es) | 2000-10-26 | 2004-08-12 | Johnson & Johnson | Dispositivos de suministro transdermico de farmaco que tienen microrresaltos recubiertos. |
US6766319B1 (en) | 2000-10-31 | 2004-07-20 | Robert J. Might | Method and apparatus for gathering and evaluating information |
US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
EA007063B1 (ru) | 2001-11-01 | 2006-06-30 | Янссен Фармацевтика Н.В. | ПРОИЗВОДНЫЕ АМИНОБЕНЗАМИДОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ГЛИКОГЕНСИНТАЗА-КИНАЗЫ 3β; |
DK1321139T3 (da) | 2001-12-21 | 2007-01-02 | Chiesi Farma Spa | 2-indanylaminoderivater til behandling af kronisk, akut eller inflammatorisk smerte |
EP1474145B1 (en) | 2002-02-04 | 2008-04-23 | F. Hoffmann-La Roche Ag | Quinoline derivatives as npy antagonists |
US20040156869A1 (en) | 2002-12-13 | 2004-08-12 | Neurogen Corporation | 2-substituted quinazolin-4-ylamine analogues |
AU2004220112A1 (en) | 2003-03-07 | 2004-09-23 | Eli Lilly And Company | 6-substituted nicotinamide derivatives as opioid receptor antagonists |
US7718674B2 (en) * | 2004-09-27 | 2010-05-18 | Bridge Pharma, Inc. | Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine |
US20060079558A1 (en) | 2004-09-27 | 2006-04-13 | Bridge Pharma. Inc. | R-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics |
EP1659113A1 (en) | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
EP1655283A1 (en) | 2004-11-08 | 2006-05-10 | Evotec OAI AG | 11beta-HSD1 Inhibitors |
EP1848498A4 (en) | 2004-11-18 | 2009-12-16 | Transpharma Medical Ltd | ASSOCIATED MICRO-CHANNEL PRODUCTION AND IONTOPHORESIS FOR TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS |
US20090137628A1 (en) * | 2005-09-23 | 2009-05-28 | Bridge Pharma, Inc. | Formulations of Indanylamines and the Use Thereof as Local Anesthetics and as Medication for Chronic Pain |
KR20080067361A (ko) * | 2005-10-28 | 2008-07-18 | 아보트 러보러터리즈 | Trpv1 수용체를 억제하는 인다졸 유도체 |
GB0525029D0 (en) | 2005-12-08 | 2006-01-18 | Univ Hull | Receptor Antagonist |
TWI409256B (zh) | 2006-09-01 | 2013-09-21 | Dow Agrosciences Llc | 殺蟲性之n-取代(雜芳基)環烷基磺醯亞胺 |
TWI383970B (zh) | 2006-11-08 | 2013-02-01 | Dow Agrosciences Llc | 多取代的吡啶基磺醯亞胺及其作為殺蟲劑之用途 |
WO2008063603A2 (en) * | 2006-11-20 | 2008-05-29 | President And Fellows Of Harvard College | Methods, compositions, and kits for treating pain and pruritis |
DK2114885T3 (en) | 2007-02-09 | 2016-05-09 | Dow Agrosciences Llc | A process for the oxidation of certain substituted sulfiliminer for insecticidal sulfoximines |
US7511149B2 (en) | 2007-02-09 | 2009-03-31 | Dow Agrosciences Llc | Process for the oxidation of certain substituted sulfilimines to insecticidal sulfoximines |
WO2008099022A1 (en) | 2007-02-16 | 2008-08-21 | Tibotec Pharmaceuticals Ltd. | 10-sulfonyl-dibenzodiazepinones useful as hepatitis c virus inhibitors |
EP2225236B1 (de) | 2007-11-22 | 2016-01-27 | Boehringer Ingelheim International GmbH | Organische verbindungen |
EP2225237A2 (de) | 2007-11-22 | 2010-09-08 | Boehringer Ingelheim International GmbH | Organische verbindungen |
EP2062889A1 (de) | 2007-11-22 | 2009-05-27 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verbindungen |
EP2225223B1 (de) | 2007-11-22 | 2017-01-11 | Boehringer Ingelheim International GmbH | Organische verbindungen |
CA2717042A1 (en) | 2008-03-11 | 2009-09-17 | The General Hospital Corporation | Methods, compositions, and kits for treating pain and pruritis |
AU2009283085A1 (en) | 2008-08-20 | 2010-02-25 | Merck Sharp & Dohme Corp. | Non-amidic linkers with branched termini as CGRP receptor antagonists |
CA2767646C (en) | 2009-07-10 | 2019-01-29 | President And Fellows Of Harvard College | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
-
2012
- 2012-02-18 EP EP18157055.7A patent/EP3363437B8/en active Active
- 2012-02-18 CA CA2826648A patent/CA2826648C/en active Active
- 2012-02-18 DK DK18157055.7T patent/DK3363437T3/da active
- 2012-02-18 JP JP2013554666A patent/JP6184328B2/ja active Active
- 2012-02-18 WO PCT/US2012/025759 patent/WO2012112969A1/en active Application Filing
- 2012-02-18 UA UAA201311103A patent/UA112769C2/uk unknown
- 2012-02-18 KR KR1020207031145A patent/KR20200125765A/ko not_active Application Discontinuation
- 2012-02-18 KR KR1020187018400A patent/KR102014203B1/ko active IP Right Grant
- 2012-02-18 KR KR1020137023468A patent/KR101938684B1/ko active IP Right Grant
- 2012-02-18 CN CN201280016004.8A patent/CN103547566B/zh active Active
- 2012-02-18 EP EP12706985.4A patent/EP2675787B1/en active Active
- 2012-02-18 DK DK12706985.4T patent/DK2675787T3/en active
- 2012-02-18 AU AU2012219254A patent/AU2012219254B2/en active Active
- 2012-02-18 RU RU2016151688A patent/RU2016151688A/ru not_active Application Discontinuation
- 2012-02-18 KR KR1020197024272A patent/KR102173572B1/ko active IP Right Grant
- 2012-02-18 ES ES12706985.4T patent/ES2675510T3/es active Active
- 2012-02-18 ES ES18157055T patent/ES2898910T3/es active Active
- 2012-02-18 MX MX2013009537A patent/MX348961B/es active IP Right Grant
- 2012-02-18 RU RU2013142433A patent/RU2612959C2/ru not_active IP Right Cessation
- 2012-02-18 BR BR112013020874-0A patent/BR112013020874A2/pt not_active Application Discontinuation
- 2012-02-18 EP EP21187447.4A patent/EP3970723A1/en active Pending
- 2012-02-18 CN CN201710350820.7A patent/CN107540599B/zh active Active
- 2012-02-18 US US13/400,039 patent/US8865741B2/en active Active
-
2013
- 2013-08-15 IL IL227967A patent/IL227967A/en active IP Right Grant
-
2016
- 2016-11-11 AU AU2016256819A patent/AU2016256819C1/en not_active Ceased
-
2018
- 2018-07-04 HK HK18108618.5A patent/HK1248704A1/zh unknown
- 2018-11-09 AU AU2018260936A patent/AU2018260936B2/en active Active
-
2020
- 2020-11-26 AU AU2020277232A patent/AU2020277232C1/en active Active
-
2023
- 2023-04-06 AU AU2023202157A patent/AU2023202157A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013020874A2 (pt) | composto, regime, método para a preparação do referido composto, e, uso de um composto | |
BR112016013734A2 (pt) | Composto, composição farmacêutica, kit, e uso de um composto | |
CL2018002009A1 (es) | Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras. | |
BR112016000975A8 (pt) | esteróides neuroativos, composições os compreendendo e uso dos mesmos | |
EA201490396A1 (ru) | Ингибиторы репликации вирусов гриппа | |
BR112013002484A2 (pt) | composto, composição farmacêutica, métodos para tratar esclerose múltipla e artrite reumatoide, e, uso de um composto. | |
EA201791916A1 (ru) | 2'-замещенные карбануклеозидные аналоги для противовирусного лечения | |
BR112015022514A2 (pt) | composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial | |
CO7131380A2 (es) | Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1 | |
BR112015027964A2 (pt) | Compostos moduladores do regulador de condutância transmembrana da fibrose cística (cftr), composições farmacêuticas compreendendo os mesmos e uso destes para o tratamento da fibrose cística | |
NI201500142A (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos. | |
EA201590450A1 (ru) | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b | |
BR112014029868A2 (pt) | compostos, e, composição farmacêutica | |
MX2013006846A (es) | Inhibidores de la replicacion de los virus de la influenza. | |
BR112015005817A2 (pt) | compostos de bis(fluoroalquil)-1,4-benzodiazepinona como inibidores de notch | |
EA201070327A1 (ru) | Катехоламиновые производные и их пролекарства | |
EA201201658A1 (ru) | Производные пиперидина и их применение для лечения метаболических нарушений | |
EA201400567A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛАМИНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3 | |
EA201400771A1 (ru) | Новые производные азетидина, фармацевтические композиции и их применение | |
MX2014002112A (es) | Compuestos de pirimido-piridazinona y uso de los mismos. | |
BR112015018491A2 (pt) | triterpenoides c-19-modificados com atividade inibidora de maturação de hiv | |
EA201590562A1 (ru) | Бензамиды | |
EA201391525A1 (ru) | Гликозидные производные и их применение для лечения диабета | |
BR112019006216A2 (pt) | compostos de p2x3 e/ou p2x2/3 e métodos | |
EA201401231A1 (ru) | Фармацевтические комбинации, предназначенные для лечения метаболических нарушений |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B12F | Other appeals [chapter 12.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: ASANA BIOSCIENCES, LLC (US) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |